Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZW) Total Non-Current Liabilities (2021 - 2025)

Core Scientific (CORZW) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $3.2 billion as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 142.57% to $3.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 billion through Dec 2025, up 142.57% year-over-year, with the annual reading at $3.2 billion for FY2025, 142.57% up from the prior year.
  • Total Non-Current Liabilities hit $3.2 billion in Q4 2025 for Core Scientific, up from $3.1 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $3.2 billion in Q4 2025 to a low of $12.9 million in Q1 2021.
  • Historically, Total Non-Current Liabilities has averaged $1.2 billion across 5 years, with a median of $1.3 billion in 2022.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 11709.1% in 2022 and later tumbled 86.55% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $1.1 billion in 2021, then increased by 15.35% to $1.2 billion in 2022, then rose by 7.76% to $1.3 billion in 2023, then grew by 0.96% to $1.3 billion in 2024, then skyrocketed by 142.57% to $3.2 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for CORZW at $3.2 billion in Q4 2025, $3.1 billion in Q3 2025, and $2.9 billion in Q2 2025.